Trailblazing Alzheimer’s Drugs Move Into Late-Stage Development
Executive Summary
Medivation's Dimebon, Elan/Wyeth's bapineuzumab and AstraZeneca/Targacept's AZD3480 are among several novel drugs targeting new mechanisms of action that are now moving into later stages of development for Alzheimer's disease
You may also be interested in...
Anti-Amyloid Still All The RAGE At Alzheimer’s Disease Conference
A little more than a week after an article published in The Lancet raised questions about the assumption that removing amyloid plaque is key to modifying Alzheimer's disease - an assumption upon which most drug makers are pinning their hopes - Wyeth, Lilly and Pfizer unveiled data on their respective agents at the International Conference on Alzheimer's Disease in Chicago
Anti-Amyloid Still All The RAGE At Alzheimer’s Disease Conference
A little more than a week after an article published in The Lancet raised questions about the assumption that removing amyloid plaque is key to modifying Alzheimer's disease - an assumption upon which most drug makers are pinning their hopes - Wyeth, Lilly and Pfizer unveiled data on their respective agents at the International Conference on Alzheimer's Disease in Chicago
JPMorgan Healthcare Conference In Brief
GSK plans for Avandia rebound: After finalizing the labeling changes for Avandia (rosiglitazone), GlaxoSmithKline is seeking to jumpstart sales of the type 2 diabetes drug, which plummeted in 2006 due to cardiovascular safety concerns. GSK got the best possible label, stating that the risk is "inconclusive" and does not draw a distinction between Avandia and other oral anti-diabetics (1"The Pink Sheet" Nov. 19, 2007, p. 3). "Can we get it back on track? ... The consensus on Avandia is that no, you can't. ... [Financial analysts] expect that we will not be able to restore health on Avandia in the U.S.," outgoing CEO JP Garnier said Jan. 8 at the JPMorgan Healthcare conference. "Well we're going to try to prove that wrong, and we're certainly going to push the drug." He advised investors not to expect an uptick in sales before June or July. "We have to give it the best shot because, frankly, the medicine needs to be used and deserves to be used, and is no different from the rest," Garnier added. "I think we can counter this negative media and very clumsy reporting with facts and data and FDA support"...